Who
Jarrod Longcor
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Cellectar Biosciences.
In numbers
- Trades disclosed
- 29
- Buys
- 7
- Sells
- 1
- Bought
- $225K
- Sold
- $15K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Jul 2016
- Last trade
- 7 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —118,000 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —118,000 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $25K8,680 at $2.88 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $26026,040 at $0.01 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $26026,040 at $0.01 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $25K8,680 at $2.88 | filing |
| 2 Jul 2025filed 3 Jul 2025 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $10010,000 at $0.01 | filing |
| 2 Jul 2025filed 3 Jul 2025 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $50K10,000 at $4.99 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 10 Jan 2025filed 12 Mar 2025 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $8,40030,000 at $0.28 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 8 Dec 2023filed 12 Dec 2023 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Code A | —42,927 at $0.00 | filing |
| 23 Jun 2023filed 12 Dec 2023 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,000 at $0.00 | filing |
| 17 Jan 2023filed 18 Jan 2023 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,000 at $0.00 | filing |
| 25 Jan 2022filed 27 Jan 2022 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —475,000 at $0.00 | filing |
| 4 Mar 2021filed 5 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 28 Dec 2020filed 28 Dec 2020 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $40K29,630 at $1.35 | filing |
| 5 Jun 2020filed 8 Jun 2020 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $32632,609 at $0.01 | filing |
| 5 Jun 2020filed 8 Jun 2020 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $75K65,218 at $1.15 | filing |
| 3 Feb 2020filed 5 Mar 2020 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström PatientsCLRB · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name Jarrod Longcor; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.